1
|
Ji C, Zhu L, Fang L. Hsa_circ_0000851 promotes PDK1/p-AKT-mediated cell proliferation and migration by regulating miR-1183 in triple-negative breast cancer. Cell Signal 2023; 101:110494. [PMID: 36241055 DOI: 10.1016/j.cellsig.2022.110494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 09/30/2022] [Accepted: 10/05/2022] [Indexed: 11/07/2022]
Abstract
Breast cancer (BC) is the most common cause of cancer-related mortality in women worldwide. Circular RNAs (circRNAs), a type of non-coding RNA, have garnered interest because of their unique looped structure. In recent years, circRNAs have been shown to be involved in various diseases, including carcinogenesis, and to serve as biomarkers for early risk assessment and survival prediction of different tumour types. This study aimed to identify a novel circRNA, hsa_circ_0000851, generated from the sixth intron of the oncogene TCF4, reported to be involved in BC pathogenesis. Our study showed that hsa_circ_0000851 was mainly located in the cytoplasm of BC cells and upregulated in BC cell lines and tissue samples. Higher hsa_circ_0000851 expression levels resulted in increased proliferation of BC cells both in vitro and in vivo, while treatment of BC cells with hsa_circ_0000851 siRNA decreased their proliferation. We found that hsa_circ_0000851 bound directly to miR-1183, accelerating the expression of its target gene PDK1, which facilities BC cell proliferation and migration through PDK1/p-AKT.
Collapse
|
2
|
Chen Q, Han H, Lin F, Yang L, Feng L, Lai X, Wen Z, Yang M, Wang C, Ma Y, Yin T, Lu G, Lin H, Qi J, Yang Y. Novel shikonin derivatives suppress cell proliferation, migration and induce apoptosis in human triple-negative breast cancer cells via regulating PDK1/PDHC axis. Life Sci 2022; 310:121077. [DOI: 10.1016/j.lfs.2022.121077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 10/03/2022] [Accepted: 10/11/2022] [Indexed: 11/05/2022]
|
3
|
Wang X, Shen X, Yan Y, Li H. Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications. Biosci Rep 2021; 41:BSR20204402. [PMID: 33739396 DOI: 10.1042/BSR20204402] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 03/12/2021] [Accepted: 03/17/2021] [Indexed: 01/01/2023] Open
Abstract
Pyruvate dehydrogenase kinase (PDK) can regulate the catalytic activity of pyruvate decarboxylation oxidation via the mitochondrial pyruvate dehydrogenase complex, and it further links glycolysis with the tricarboxylic acid cycle and ATP generation. This review seeks to elucidate the regulation of PDK activity in different species, mainly mammals, and the role of PDK inhibitors in preventing increased blood glucose, reducing injury caused by myocardial ischemia, and inducing apoptosis of tumor cells. Regulations of PDKs expression or activity represent a very promising approach for treatment of metabolic diseases including diabetes, heart failure, and cancer. The future research and development could be more focused on the biochemical understanding of the diseases, which would help understand the cellular energy metabolism and its regulation by pharmacological effectors of PDKs.
Collapse
|
4
|
Fortarezza F, Pezzuto F, Cazzato G, Punzo C, d’Amati A, Lettini T, Gentile M, Buonadonna AL, Mariano M, Pezzolla A, Serio G. Bilateral Phyllodes Giant Tumor. A Case Report Analyzed by Array-CGH. Diagnostics (Basel) 2020; 10:diagnostics10100825. [PMID: 33076253 PMCID: PMC7602371 DOI: 10.3390/diagnostics10100825] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 10/07/2020] [Accepted: 10/09/2020] [Indexed: 02/05/2023] Open
Abstract
The breast phyllodes tumor is a biphasic tumor that accounts for less than of 1% of all breast neoplasms. It is classified as benign, borderline, or malignant, and can mimic benign masses. Some recurrent alterations have been identified. However, a precise molecular classification of these tumors has not yet been established. Herein, we describe a case of a 43-year-old woman that was admitted to the emergency room for a significant bleeding from the breast skin. A voluminous ulcerative mass of the left breast and multiple nodules with micro-calcifications on the right side were detected at a physical examination. A left total mastectomy and a nodulectomy of the right breast was performed. The histological diagnosis of the surgical specimens reported a bilateral giant phyllodes tumor, showing malignant features on the left and borderline characteristics associated with a fibroadenoma on the right. A further molecular analysis was carried out by an array-Comparative Genomic Hybridization (CGH) to characterize copy-number alterations. Many losses were detected in the malignant mass, involving several tumor suppressor genes. These findings could explain the malignant growth and the metastatic risk. In our study, genomic profiling by an array-CGH revealed a greater chromosomal instability in the borderline mass (40 total defects) than in the malignant (19 total defects) giant phyllodes tumor, reflecting the tumor heterogeneity. Should our results be confirmed with more sensitive and specific molecular tests (DNA sequencing and FISH analysis), they could allow a better selection of patients with adverse pathological features, thus optimizing and improving patient's management.
Collapse
Affiliation(s)
- Francesco Fortarezza
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Pathology Unit, University of Padova, 35121 Padova, Italy; (F.F.); (F.P.)
| | - Federica Pezzuto
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Pathology Unit, University of Padova, 35121 Padova, Italy; (F.F.); (F.P.)
| | - Gerardo Cazzato
- Department of Emergency and Organ Transplantation (DETO), Pathology Section, Breast Unit Care, University of Bari, Medical School, 70124 Bari, Italy; (G.C.); (A.d.); (T.L.); (M.M.)
| | - Clelia Punzo
- Department of Emergency and Organ Transplantation (DETO), Surgery Section, Breast Unit Care, University of Bari, Medical School, 70124 Bari, Italy; (C.P.); (A.P.)
| | - Antonio d’Amati
- Department of Emergency and Organ Transplantation (DETO), Pathology Section, Breast Unit Care, University of Bari, Medical School, 70124 Bari, Italy; (G.C.); (A.d.); (T.L.); (M.M.)
| | - Teresa Lettini
- Department of Emergency and Organ Transplantation (DETO), Pathology Section, Breast Unit Care, University of Bari, Medical School, 70124 Bari, Italy; (G.C.); (A.d.); (T.L.); (M.M.)
| | - Mattia Gentile
- Medical Genetics, “Di Venere” Hospital, 70131 Carbonara (Bari), Italy; (M.G.); (A.L.B.)
| | | | - Marta Mariano
- Department of Emergency and Organ Transplantation (DETO), Pathology Section, Breast Unit Care, University of Bari, Medical School, 70124 Bari, Italy; (G.C.); (A.d.); (T.L.); (M.M.)
| | - Angela Pezzolla
- Department of Emergency and Organ Transplantation (DETO), Surgery Section, Breast Unit Care, University of Bari, Medical School, 70124 Bari, Italy; (C.P.); (A.P.)
| | - Gabriella Serio
- Department of Emergency and Organ Transplantation (DETO), Pathology Section, Breast Unit Care, University of Bari, Medical School, 70124 Bari, Italy; (G.C.); (A.d.); (T.L.); (M.M.)
- Correspondence: ; Tel.: +39-080-5474368
| |
Collapse
|